Note 14 - Subsequent Events	3 Months Ended
Mar. 31, 2026
Notes to Financial Statements
Subsequent Events [Text Block]	*Note 14.* Subsequent Events The Company has evaluated subsequent events through the date of the filing of this Quarterly Report and report the following. Stock Issuances** Subsequent to March 31, 2026, we have sold 1,050,000 shares of our common stock to Clearthink (see Note 3) and received $147,033 in gross proceeds. Clyra Medical Financing Activities Subsequent to March 31, 2026, Clyra issued guaranteed promissory notes in the aggregate amount of $775,125 to seven accredited investors. The notes bear interest at the rate of 15% per annum, mature February 28, 2029, and are guaranteed by the Company’s largest stockholder, BioLargo Inc. Each investor received a warrant to purchase an aggregate of number of Clyra common shares equal to the face amount of the note divided by 7.5, divided by two, at an exercise price of $7.50 per share, expiring February 28, 2031. Warrants to purchase 51,675 shares of Clyra common stock were issued to the investors. BioLargo Energy (BETI) Financing Activities Subsequent to March 31, 2026, BETI sold 6,757 shares of its common stock at $3.70 per share to one accredited investor and received $25,000 in gross and net proceeds.

Note 14 - Subsequent Events

3 Months Ended

Mar. 31, 2026

Note 14. Subsequent Events

The Company has evaluated subsequent events through the date of the filing of this Quarterly Report and report the following.

Stock Issuances

Subsequent to March 31, 2026, we have sold 1,050,000 shares of our common stock to Clearthink (see Note 3) and received $147,033 in gross proceeds.

Clyra Medical Financing Activities

Subsequent to March 31, 2026, Clyra issued guaranteed promissory notes in the aggregate amount of $775,125 to seven accredited investors. The notes bear interest at the rate of 15% per annum, mature February 28, 2029, and are guaranteed by the Company’s largest stockholder, BioLargo Inc. Each investor received a warrant to purchase an aggregate of number of Clyra common shares equal to the face amount of the note divided by 7.5, divided by two, at an exercise price of $7.50 per share, expiring February 28, 2031. Warrants to purchase 51,675 shares of Clyra common stock were issued to the investors.

BioLargo Energy (BETI) Financing Activities

Subsequent to March 31, 2026, BETI sold 6,757 shares of its common stock at $3.70 per share to one accredited investor and received $25,000 in gross and net proceeds.